BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) represents European small and medium-sized biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance, including small molecule antibiotics, biologics, products with a prophylaxis indication, and new technologies that include microbiome-based and phage-based therapies, immune targeting therapies, and anti-biofilm agents. BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe. BEAM recommends bold incentives that warrant action by policymakers to stimulate much needed innovation.
· Florence Séjourné ( bio ), President. Da Volterra (Paris, France)
BEAM ALLIANCE IN NUMBERS
Product in the market
Products in preclinical research
Products in clinical development
|Pre-clinical||Novamycin®||Invasive Fungal Disease|
|IND/CTA ready||Lynovex® inhaled||Cystic Fibrosis|
|Phase II||Lynovex® oral||Cystic Fibrosis|
|Lead opt||Antivirulence Gram -||Preventive treatment for patient at risk of nosocomial infection by Enterobacteriaceae|
|Lead opt||Antivirulence Gram +||Preventive treatment for patient at risk of nosocomial infection by Staphylococci, Streptococci and Enterococci|
|Lead opt||DAB PO||Oral inhibitor of Beta-lactamases to be used in combination with a 3rd generation cephalosporine against ESBL/OXA-48/KPC expressing Enterobacteriaceae|
|Lead opt||DAB||Direct acting antibiotic (IV) against multi-drug resistant enterobacteriaceae (CRE) and/or P. aeruginosa|
DescriptionAiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.
InvestorsSanto Holding (Deutschland) GmbH and other private investors
|Phase I||AIC499 - a Superior Gram-negative Resistance Breaker||Gram-negative resistance breaker|
DescriptionMotif Bio is a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings. Motif is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram positive and Gram negative bacteria
|Pre-clinical||Iclaprim||Staphylococcus aureus Lung Infections Among Cystic Fibrosis Patients|
|Pre-clinical||HY-006||Pulmonary Cystic Fibrosis|
|Phase II||HY-005||Skin & Soft Tissue MRSA|
|Phase II||HY-004||Nasal MRSA decolonisation|
|Phase I completed||HY-002||Intra-Abdominal Infections|
|Phase I completed||HY-001||Urinary Tract Infections|
DescriptionDestiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future. Destiny Pharma anti-microbial drug productsDestiny Pharma’s Vision is of an expanding range of new antimicrobial drug products which operate within existing antibiotic markets but due to their unique features, open significant, new markets that are closed to traditional antibiotics due to the existence or threat of antibiotic resistance. The proprietary, new antimicrobial drug platform at Destiny Pharma, the XF Drug Series, act via an ultra-rapid action which kill bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance response.
|Pre-clinical||XF-70||Dermal burn wound infections|
|Pre-clinical||XF-73||Hospital pneumonia/ventilator-associated pneumonia (VAP)|
|Phase II||XF-73||Post-surgical nasal decolonisation|
|Lead opt||Novel bacterial Topoisomerase Inhibitor||Hospital acquired Pneumonia|
|Lead opt||Novel tri-cyclic topoisomerase inhibitor||Complicated skin and skin structure infections|
|Pre-clinical||SASPject™ PT3.8||Serious Pseudomonas Aeruginosa infections where treatment options are limited|
|Pre-clinical||SASPject™ PT5||Serious E.coli infections where treatment options are limited|
|Pre-clinical||SASPject™ PT4||Serious Klebsiella Pneumoniae infections where treatment options are limited|
DescriptionCentauri has developed a proprietary platform ("Alphamers") that redirect pre-existing natural immunity to fight MDR bacterial infections.
|Pre-clinical||Pseudomonas Aeruginosa specific Inhibitor||Undisclosed|
|Pre-clinical||Broad spectrum Gram negative Inhibitor||Undisclosed|
DescriptionCombioxin SA develops innovative anti-virulence treatments for bacterial infections. CAL02 is a clinical-stage first-in-class drug that neutralizes deadly toxins produced by a large panel of bacteria, including multi-resistant strains. CAL02 aims at saving lives, protecting against long-term consequences from severe infections and fighting antibiotic resistance.
|Phase I||CAL02||Severe infections|
DescriptionNeem Biotech is a Wales-based R&D life sciences centre that brings with it significant expertise in the biology and chemistry of bioactive compounds, and transforms these into platform technology resources for application in the fight against global threats to human and animal health. This includes antimicrobial resistance. Particular areas of research interest include cystic fibrosis and controlling infection in the healing of chronic wounds. Neem is fully owned by the life-science group Zaluvida. Neem Biotech’s aim is to enhance the life expectancy of patients and the quality of life of both patients and their families.
|Pre-clinical||NX-AS-401||Chronic respiratory infections in cystic fibrosis|
|Lead opt||Anti Virulence in Gram negative bacteria||gram negative infections|
|Lead opt||Anti-Biofilm for Staphylococcus aureus||systemic|
|Pre-clinical||Adjuvant reversing resistance and potentiating Ethionamide activity in Tuberculosis||Tuberculosis|
|Discovery||Chlamydia||Trachoma, Chlamydia eye infection|
|Lead opt||Chlamydia||Genital Chlamydia infection|
|Lead opt||GmP's against VRE and MRSA||VRE and MRSA|
|Pre-clinical||Mtb Tolerance Inhibitor||MDR Tuberculosis|
DescriptionAuspherix is an anti-infectives company that is developing a novel class of organogold-based antibiotics that are designed to help address the worldwide healthcare crisis of rising antimicrobial resistance (AMR).
InvestorsBrandon Capital and IP Group
|Pre-clinical||Novel class of organogold antibiotics||cUTI|
DescriptionBasilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company. Through its Swiss subsidiary Basilea Pharmaceutica International Ltd. the company is developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
InvestorsListed on the SIX Swiss Exchange (SIX: BSLN)
|Phase III||Ceftobiprole||Acute bacterial skin and skin structure infections, Staphylococcus aureus bacteremia|
|Marketed||Ceftobiprole||Community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia)|